A billionaire-backed biotechnology startup called R3 Bio is developing genetically-engineered organ systems without brains as an alternative to animal testing in laboratories.

The company's approach involves creating what they term "organ sacks" - whole organ systems that are engineered to lack brain tissue. These biological systems are designed to serve as testing platforms for pharmaceutical and medical research that currently relies on laboratory animals.

According to company cofounders, the technology represents a potential breakthrough in addressing ethical concerns around animal testing while potentially providing more accurate biological models for research. The organ systems would function as complete biological units capable of responding to treatments and interventions.

The long-term vision for R3 Bio extends beyond animal replacement models. Company leadership has indicated their ultimate goal is to develop human versions of these organ systems, which could revolutionize both medical testing and potentially organ transplantation research.

The startup has secured significant financial backing from billionaire investors, though specific funding amounts and investor names were not disclosed. The technology is still in development stages, and the company has not announced timelines for commercial availability or regulatory approval processes.